Ronald J. Daniels is Director at BridgeBio Pharma, Inc. (BBIO). They have made 4 open-market trades across 1 company since 2021, most recently 2026-06-22.
CIK 0001164475
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $448K since 2021, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| BBIO | 20,981 | $1.4M |
Shares reported on the most recent Form 4, priced at the 2026-06-24 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.